Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

Regen BioPharma, Inc. (RGBPP)

0.0581
0.0000
(0.00%)
At close: April 23 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
236.5600
236.5600
235.5170
171.1940
110
Operating Expense
627.4650
923.5090
575.1220
371.9640
319.3170
Operating Income
-390.9050
-686.9490
-339.6050
-200.7700
-209.3170
Net Non Operating Interest Income Expense
-331.3680
-309.4480
-254.8320
-366.7980
-942.9330
Other Income Expense
-205.1080
2,152.9050
3,037.9690
-6,197.6640
4,566.6690
Pretax Income
-927.3810
1,156.5080
2,443.5320
-6,765.2320
3,414.4190
Net Income Common Stockholders
-882.5950
1,023.5080
2,227.0340
-6,765.2330
2,731.5350
Diluted NI Available to Com Stockholders
-882.5950
1,023.5080
2,227.0340
-6,765.2330
2,731.5350
Total Operating Income as Reported
-390.9060
-686.9500
-339.6050
-200.7710
-209.3170
Rent Expense Supplemental
69.7150
60
50
25
18.5480
Total Expenses
627.4650
923.5090
575.1220
371.9640
319.3170
Net Income from Continuing & Discontinued Operation
-882.5950
1,023.5080
2,227.0340
-6,765.2330
2,731.5350
Normalized Income
-677.4870
-677.2869
-360.4285
-567.5690
-602.1334
Interest Income
--
--
0.4550
0.2300
--
Interest Expense
81.3680
59.4480
209.7870
367.0280
942.9330
Net Interest Income
-331.3680
-309.4480
-254.8320
-366.7980
-942.9330
EBIT
-846.0130
1,215.9560
2,653.3190
-6,398.2040
4,357.3520
EBITDA
-846.0130
1,215.9560
2,653.3190
-6,398.2040
4,357.3520
Net Income from Continuing Operation Net Minority Interest
-882.5950
1,023.5080
2,227.0340
-6,765.2330
2,731.5350
Total Unusual Items Excluding Goodwill
-205.1080
2,152.9050
3,275.2690
-6,197.6640
4,566.6690
Total Unusual Items
-205.1080
2,152.9050
3,275.2690
-6,197.6640
4,566.6690
Normalized EBITDA
-640.9050
-936.9490
-621.9500
-200.5400
-209.3170
Tax Rate for Calcs
--
0.0002
0.0002
--
0.0003
Tax Effect of Unusual Items
--
452.1101
687.8065
--
1,233.0006
9/30/2020 - 4/20/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARDS Aridis Pharmaceuticals, Inc.
0.0001
0.00%
 
GTBP GT Biopharma, Inc.
2.2300
+2.29%
 
BRTX BioRestorative Therapies, Inc.
1.7300
+0.58%
 
ALZN Alzamend Neuro, Inc.
0.6851
-0.71%
 
ADCT ADC Therapeutics SA
1.2900
+4.88%
 
ATNM Actinium Pharmaceuticals, Inc.
1.3000
-5.80%
 
ARQT Arcutis Biotherapeutics, Inc.
14.45
+4.48%
 
BEAM Beam Therapeutics Inc.
19.87
+3.87%
 
ADMA ADMA Biologics, Inc.
21.73
+1.59%
 
NWBO Northwest Biotherapeutics, Inc.
0.3600
+0.56%